All Updates

All Updates

icon
Filter
Product updates
Tempus announces new testing solutions for HER2-/FOLR1-expressing tumors
Precision Medicine
Jun 2, 2024
Last week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

Jun 2, 2024

Tempus announces new testing solutions for HER2-/FOLR1-expressing tumors

Product updates

  • Tempus has launched a suite of new testing solutions to help doctors identify patients with HER2- or FOLR1-expressing tumors, potentially making them suitable candidates for specific medicines, such as antibody-drug conjugates.

  • The new solutions focus on testing for HER2 and FOLR1 through immunohistochemistry (IHC). Alongside this, Temps offers next-generation sequencing assays, and these new tests are available to supplement those assays. Moreover, these tests are now available for all solid tumor cancers. HER2 and FOLR1 tests are recommended for several types of cancer. 

  • According to Tempus, these new diagnostic tools will provide physicians with the means to identify which therapies could be most beneficial for their patients. By identifying the presence of markers like HER2, it is believed that these tests can provide insights into the effectiveness of certain treatments and can potentially enhance a patient’s treatment outcome.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.